ERBB2 and neoplasm: Regardless, data are emerging regarding the potential T-DXd benefit among patients without HER2 amplification and trials in HER2 “ultra-low” (i.e., HER2 IHC 0 with incomplete and faint staining in ≤10% of tumor cells) are underway [25,26].